Contract analysis

I. EXECUTIVE SUMMARY The purpose of this memorandum is to provide a comprehensive analysis of the litigation risk, probable outcome modeling, and settlement economics in the above-captioned action, and to recommend a settlement authorization range for use in any mediation or direct negotiations with Lumicore Technologies, Inc. ("Lumicore" or "Defendant") and its litigation counsel, Hawthorne Vega & Cruz LLP. This mem

II. CASE STATUS AND PROCEDURAL POSTURE A. Current Procedural Status This action was commenced on April 22, 2024, by the filing of a Complaint for Patent Infringement in the United States District Court for the Eastern District of Texas, marshall Division. The case was assigned to Judge James R. Gilstrap, one of the most experienced patent jurists in the country, under Case No. 2:24-cv-00319-JRG. The Eastern District

1. Dr. Jian-Wei Huang, Chief Technology Officer of OWS — deposed November 5, 2024 (noted for future scheduling; date reflects our projected timeline).

2. Dr. Sandra Michaud, Chief Technology Officer of Lumicore — deposed November 19, 2024 (projected).

3. Raymond Bautista, General Counsel of Lumicore — deposed December 3, 2024 (projected; testimony limited by privilege assertions that are the subject of the pending Motion to Compel).

4. Angela Reeves, Managing Director of FairPoint Licensing Group — deposed December 10, 2024 (projected).

5. Kevin Ng, Senior Analyst at Benchmark Semiconductor Analysis — deposed January 7, 2025 (projected). Approximately 12 additional fact depositions and all expert depositions remain to be completed before the close of expert discovery on August 15, 2025. The remaining fact depositions include key Lumicore engineering personnel involved in the design of the accused products, OWS sales and marketing personnel with know

III. ASSESSMENT OF LIABILITY A. Infringement — Strength of Case

1. Literal Infringement C&H's overall assessment of the strength of OWS's literal infringement case is strong. We estimate a 75% probability of prevailing on infringement with respect to at least two of the four asserted patents and at least one accused product line, and a 60–65% probability of prevailing on all four patents across all three accused product lines. The following patent-by-patent analysis supports this

2. Doctrine of Equivalents OWS has asserted infringement under the doctrine of equivalents ("DOE") for specific claim limitations where literal infringement may be contested depending on the outcome of claim construction. Specifically, DOE is asserted with respect to: (a) Claims 3 and 7 of the '193 Patent, with respect to the "coherent detection module" limitation; and (b) Claim 12 of the '015 Patent, with respect to

3. Induced and Contributory Infringement Counts V and VI of the Complaint allege induced infringement under 35 U.S.C. § 271(b) and contributory infringement under 35 U.S.C. § 271(c) with respect to all four asserted patents. These claims are premised on Lumicore's sale of the accused transceiver modules to customers — primarily hyperscale data-center operators and telecommunications equipment manufacturers — who inte

1. Prior Art (23 References Cited in Invalidity Contentions) Lumicore's Invalidity Contentions, served October 14, 2024, cite a total of 23 prior-art references across the four asserted patents. C&H has conducted a comprehensive prior-art analysis in consultation with our technical expert, Dr. Caroline Ashford of the Northfield Institute of Technology, and our assessment of each patent's vulnerability is as follows.

2. Overall Validity Probability Taking into account all invalidity defenses across all four asserted patents, C&H assesses the overall validity probabilities as follows: • Probability that at least one asserted patent survives all invalidity challenges: approximately 85%. • Probability that all four patents survive: approximately 55–60%. These probabilities are incorporated into the decision-tree analysis in Section

3. Inequitable Conduct / Unenforceability Lumicore's first counterclaim alleges that the '193 Patent is unenforceable due to inequitable conduct during prosecution. Specifically, Lumicore alleges that Dr. Jian-Wei Huang, the named inventor of the '193 Patent and OWS's Chief Technology Officer, failed to disclose a prior publication — specifically, a 2015 conference paper co-authored by Dr. Huang and a former colleagu

IV. ASSESSMENT OF DAMAGES A. Theory 1: Lost Profits — Panduit Analysis Under Panduit Corp. v. Stahlin Bros. Fibre Works, Inc., 575 F.2d 1152 (6th Cir. 1978), a patentee may recover lost profits upon demonstrating: (1) demand for the patented product; (2) absence of acceptable non-infringing substitutes; (3) manufacturing and marketing capability to exploit the demand; and (4) the amount of profit that would have been